High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 5, 1999, Pages 766-769

  Delgado, Juan ^a   Macías, Juan ^a   Pineda, Juan A ^a   Corzo, Juan E ^b   González Moreno, Paz ^a   De La Rosa, Rafael ^a   Sánchez Quijano, Armando ^a   Leal, Manuel ^a   Lissen, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; MALE; VISCERAL LEISHMANIASIS; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTOZOA;

EID: 0345237252     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.766     Document Type: Article

References (27)

1. Alvar J, Cañavate C, Gutiérrez-Solar B, Jimenez M, Laguna F, López-Velez R, Molina R, Moreno F, 1997. Leishmania and human immunodeficiency virus: the first 10 years. Clin Microbiol Rev 10: 298-319.
2. Albrecht H, Sobottka I, Emminger C, Jablonowski H, Just G, Stoehr A, Kubin T, Salzbergeret B, Lutz T, Lunzen J, 1996. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas non-endemic for Leishmania donovani. Arch Pathol Lab Med 120: 189-198.
3. Parkas V, Godwin J, Murray H, 1997. Kala-azar comes to New York. Arch Intern Med 157: 921-923.
4. Gradoni L, Bryceson A, Desjeux P, 1995. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 73: 191-197.
5. Herwald BL, Berman JD, 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of the pertinent clinical studies. Am J Trop Med Hyg 46: 296-306.
6. Altés J, Salas A, Riera M, Udina M, Galmes A, Balanzat J, Ballesteros A, Buades J, Salva F, Villalonga C, 1991. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of literature. AIDS 5: 201-207.
7. Berenguer J, Moreno S, Cercenado E, Bernaldo de Quirós JCL, García de la Fuente A, and Bouza E, 1989. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 111: 129-132.
8. Medrano FJ, Hernández-Quero J, Jiménez E, Pineda JA, Rivero A, Sanchez-Quijano, Velez ID, Viciana P, Castillo R, Reyes MJ, Carvajal F, Leal M, Lissen E, 1992. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 6: 1499-1503.
9. Montalbán C, Martínez-Fernández R, Calleja JL, García-Diaz JD, Rubio R, Dronda F, Moreno S, Yebra M, Barros C, Cobo J, Martinez MC, Ruiz F, Costa JR, 1989. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis 4: 655-660.
10. Delgado M., García MA, Martos F, Regura JM, Jiménez F, Colmenero JD, 1997. Características clínicas y evolutivas de la leishmaniasis visceral en pacientes con infección por VIH. An Med Interna 14: 506-510.
11. Ribera E, Curucull E, Ocaña I, Vallespí, Gasser I, Juste C, 1995. Leishmaniasis visceral en pacientes con infección por VIH. Enferm Infecc Microbiol Clin 13: 73-79.
12. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, Jaupert D, Boulatet O, Dereure J, Gambarelli F, Gastaut JA, Dugardin P, Dellamonica P, Cassuto JP, 1995. Visceral leishmaniasis and HIV co-infection in southern France. Trans R Soc Trop Med Hyg 89: 159-162.
13. CDC, 1992. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescent and adults. MMWK Morb Mortal Wkly Rep 41: 1-19.
14. Navin TR, Arana BA, Arana FE, Berman JD, Chajón FJ, 1992. Placebo-controlled trial of sodium stibogluconate (Pentostam) versus ketoconazol for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165: 528-534.
15. Hepburn NC, Nolan J, Herd RM, Neilson JM, Sutherland GR, 1994. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. Q J Med 87: 465-472.
16. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC, 1993. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet 342: 238-239.
17. Broeckaert-van Orshover A, Michielsen P, Vandepitte J, 1979. Fatal leishmaniasis in a renal transplant patient (letter). Lancet 2: 740-741.
18. Donovan KL, White AD, Cooke DA, Fisher DJ, 1990. Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment in a renal transplant recipient. J Infect 21: 107-110.
19. Halim MA, Alfurayh O, Kalin ME, Dammas S, Al-Eisa A, Damanhouri G, 1993. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazol in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis 16: 397-399.
20. McCarthy AE, Keystone JS, Kain KC, 1993. Pancreatitis occurring during therapy with stibogluconate: two case reports. Clin Infect Dis 17: 952-953.
21. Cortés E, Ribera E, Cucurull E, Otero J, Ocaña I, Pahissa A, 1995. Pancreatitis aguda por antimoniales en pacientes con leishmaniasis visceral e infección VIH. Med Clin (Barc) 104: 578-580.
22. Gasser RA, Magill AJ, Oster CN, Franke DE, Grögl M, Berman JD, 1994. Pancreatitis by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 18: 83-90.
23. Franco AM, Barbosa AC, Rath S, Dorea JG, 1995. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg 52: 435-437.
24. Murthy UK, DeGregorio F, Oates RP, Blair DC, 1992. Hyperamylasemia in patients with the acquired immunodeficiency syndrome. Am J Gastroenterol 87: 332-336.
25. Cappell MS, 1997. The pancreas in AIDS. Gastroenterol Clin North Am 26: 337-365.
26. Belle L, 1997. Drug interactions and toxicities in patients with AIDS. Sande MA, Volverding PA, eds. The Medical Management of AIDS. Fifth edition. Philadelphia: W. B. Saunders Company, 125-142.
27. Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz JM, 1994. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 28: 255-259.